Key Takeaways
Legend Biotech (NASDAQ: LEGN) stands at a pivotal juncture, with its flagship CAR-T therapy, CARVYKTI, increasingly demonstrating its transformative potential in multiple myeloma treatment. The recent data presented at the Tandem Meetings in February 2026, coupled with strong first-quarter sales, paints a compelling picture for the company's future growth trajectory, suggesting a bullish outlook for long-term investors. While the stock currently trades at $27.16, significantly below the analyst consensus target of $58.00, the expanding evidence for CARVYKTI's earlier use and improving operational efficiency could drive substantial upside.
The recent Tandem Meetings of ASTCT and CIBMTR, held from February 4-7, 2026, served as a critical platform for Legend Biotech to showcase new clinical and real-world data for CARVYKTI (ciltacabtagene autoleucel). Six poster presentations highlighted consistent and durable responses observed across the CARTITUDE trials, including CARTITUDE-1, CARTITUDE-2, and CARTITUDE-4. This comprehensive body of evidence strongly supports the therapy's efficacy and safety profile, particularly when administered earlier in a patient's multiple myeloma treatment journey.
A key takeaway from these presentations was the demonstration of clinically meaningful quality-adjusted survival gains. These gains were primarily driven by a prolonged period during which patients remained free from any multiple myeloma treatment, reinforcing the potential for a single CARVYKTI infusion to deliver long-lasting benefits. CEO Ying Huang, Ph.D., emphasized that these data "reinforce the potential of CARVYKTI to improve outcomes... particularly when used earlier in the treatment journey," suggesting an emerging curative potential for the therapy. This narrative is crucial for expanding CARVYKTI's market beyond heavily pre-treated patients.
The data also included real-world evidence analyses, offering valuable insights into treatment outcomes outside controlled clinical settings. This real-world validation is vital for physician adoption, as it provides confidence in CARVYKTI's performance in diverse patient populations. With over 10,000 patients treated worldwide, the growing body of clinical and real-world evidence continues to inform how CARVYKTI can be optimally used across the entire multiple myeloma treatment continuum, paving the way for broader market penetration.
Legend Biotech is actively expanding CARVYKTI's market reach, both geographically and within earlier lines of therapy. The company reported robust first-quarter 2026 results on May 12, 2026, with CARVYKTI net trade sales surging 62% year-over-year compared to Q1 2025, reaching approximately $597 million. This impressive growth was fueled by a 36% increase in U.S. net trade sales and a remarkable 222% growth in ex-U.S. net trade sales, demonstrating strong global demand.
Geographic expansion has been a significant driver, with CARVYKTI now commercially available in 18 global markets and over 300 global treatment sites, following recent launches in Italy, Poland, the Czech Republic, and Australia. This broad availability is critical for maximizing patient access and capitalizing on the therapy's growing clinical evidence. The collaboration with Johnson & Johnson (Janssen) underpins this global development and commercialization strategy, providing manufacturing scale and market access.
Perhaps the most significant opportunity lies in shifting CARVYKTI to earlier lines of therapy. The FDA and European Commission expanded CARVYKTI's approval for second-line multiple myeloma in early 2024, effectively tripling the addressable patient base. Management anticipates that the proportion of CARVYKTI patients in second and third lines of therapy, currently at 41%, will grow to approximately 75% over the next year. This shift reflects increased community adoption and earlier-line penetration, which could substantially boost future sales. Ongoing pivotal Phase 3 studies, CARTITUDE-5 (for first-line transplant-ineligible MM) and CARTITUDE-6 (for first-line transplant-eligible MM), are fully enrolled, with data expected in 2026 or 2027, which could further expand CARVYKTI's label into the lucrative first-line setting.
Legend Biotech's first-quarter 2026 financial results, reported on May 12, 2026, underscore the company's strong commercial momentum despite an adjusted net loss. Total revenue for the quarter reached $305 million, with collaboration revenue contributing $298 million and license and other revenue adding $7 million. While the reported EPS of -$0.15 missed analyst estimates, the adjusted net loss of $11 million was a significant improvement from $27 million in the same period last year. This progress reflects the increasing operating leverage as CARVYKTI sales continue to scale.
The company's gross margin on net product sales stood at 41% in Q1 2026, a decline from 57% in the previous quarter. This dip was attributed to one-time expenses associated with ramping up manufacturing capabilities. However, management expects gross margins to exceed 50% in the next quarter, indicating that these manufacturing efficiencies are temporary. Legend Biotech has made significant strides in optimizing its manufacturing, achieving a 99% success rate, a median turnaround time of approximately 29 days, and delivering over 95% on-time order releases for final product delivery during Q1 2026. The target production capacity of 10,000 CARVYKTI doses annually by end-2025 is a crucial milestone for meeting growing demand.
Legend Biotech maintains a strong balance sheet, with cash and cash equivalents, and time deposits totaling $834.6 million as of March 31, 2026. This robust cash position, coupled with no long-term debt, provides a financial runway beyond 2026. The company believes it will achieve company-wide profitability on an adjusted basis in 2026, a significant turning point for the business. Analyst consensus for FY 2029 projects revenue of $2.5 billion and EPS of $1.61, further solidifying the long-term financial outlook.
Despite CARVYKTI's impressive performance, Legend Biotech faces several risks, primarily centered around manufacturing capacity, safety profile, and an increasingly competitive landscape. Manufacturing capacity remains the central commercial bottleneck; patient demand continues to exceed supply, limiting earlier-line uptake despite favorable CARTITUDE-4 clinical data. While Legend has made strides in efficiency, scaling up to meet the projected demand for earlier-line indications will be critical. Any delays in achieving the 10,000 doses annually by end-2025 target could hinder growth.
CARVYKTI's safety profile, while well-characterized, includes significant adverse events such as Cytokine Release Syndrome (CRS), which occurred in 84% of patients in CARTITUDE-1 & -4 studies (with 4% being Grade 3 or higher). Neurologic toxicities, including Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), Parkinsonism, and Guillain-Barré syndrome, have also been reported, some severe or fatal. Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), prolonged cytopenias, and secondary hematological malignancies are also serious concerns. These safety considerations necessitate careful patient monitoring and management, which can impact treatment accessibility and physician comfort, especially in earlier lines of therapy.
The competitive landscape in multiple myeloma is intensifying. While CARVYKTI has captured market share leadership over its direct autologous CAR-T competitor, Bristol Myers Squibb's Abecma, based on superior efficacy data (e.g., CARTITUDE-1's 98% ORR vs. KarMMa-1's 73% ORR), the emergence of BCMA x CD3 bispecific antibodies like Janssen's Tecvayli and Pfizer's Elrexfio poses a threat. These "off-the-shelf" alternatives avoid the manufacturing complexity and turnaround time associated with CAR-T therapies. Additionally, allogeneic BCMA CAR-T platforms from companies like Sana Biotechnology represent a long-term disruptive threat if they can overcome current clinical challenges, potentially offering broader access and easier administration by 2030.
Considering the compelling clinical data, strong commercial execution, and clear path to profitability, Legend Biotech presents a strong investment case. The stock's current price of $27.16 is significantly below the average analyst price target of $58.00, implying substantial upside potential. Of the 19 analysts covering LEGN, 16 rate it a "Buy", with no "Sell" ratings, indicating a highly bullish consensus. This positive sentiment is reinforced by recent "Buy" and "Overweight" ratings maintained by HC Wainwright & Co. and Morgan Stanley in May 2026.
The expansion into earlier lines of therapy, particularly the anticipated growth to 75% of CARVYKTI patients in second and third lines over the next year, represents a massive market opportunity. The ongoing CARTITUDE-5 and CARTITUDE-6 trials, with data expected in 2026 or 2027, could unlock the even larger first-line market. While manufacturing bottlenecks and the competitive environment are real concerns, Legend Biotech's demonstrated ability to scale production and its strong financial position with $834.6 million in cash provide confidence in its ability to navigate these challenges.
The company's projected shift to company-wide profitability in 2026 is a critical inflection point that could attract a broader base of institutional investors. With CARVYKTI net trade sales growing at 62% year-over-year and a robust pipeline, including early-stage cell therapy programs, Legend Biotech is well-positioned for sustained growth. The current valuation appears to undervalue the long-term potential of CARVYKTI and the company's innovative cell therapy platform.
Legend Biotech's strong Q1 2026 performance, coupled with the compelling long-term data for CARVYKTI and its expanding market potential, positions the company favorably for significant growth. Investors should watch for continued manufacturing improvements, further data readouts from the CARTITUDE-5 and -6 trials, and the company's progress towards achieving profitability in 2026. The current price offers an attractive entry point for those with a long-term horizon, betting on CARVYKTI's continued dominance in the multiple myeloma treatment landscape.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
